Review
References
|
Bouillon A, Giganti D, Benedet C, Gorgette O, Pêtres S, Crublet E, Girard-Blanc C, Witkowski B, Ménard D, Nilges M, Mercereau-Puijalon O (2013). In silico screening on the three-dimensional model of the Plasmodium vivax SUB1 protease leads to the validation of a novel anti-parasite compound. J. Biol. Chem. 288(25):18561-18573. |
|
|
Campbell CO, Santiago DN, Guida WC, Manetsch R, Adams JH (2014). In silico characterization of an atypical MAPK phosphatase of Plasmodium falciparum as a suitable target for drug discovery. Chem. Biol. Drug Des. 84(2):158-168. |
|
|
Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT (2016). In silico methods for drug repurposing and pharmacology. Wiley Interdiscip. Rev. Syst. Biol. Med. 8(3):186-210. |
|
|
Kumari M, Chandra S, Tiwari N, Subbarao N (2016). 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum. BMC Struct. Biol. 16(1):12-20. |
|
|
LaMonte GM, Almaliti J, Bibo-Verdugo B, Keller L, Zou BY, Yang J. (2017). Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity. J. Med. Chem. 60(15):6721-6732. |
|
|
Lhouvum K, Ramakrishnan V, Trivedi V (2013). Insight into structural and biochemical determinants of substrate specificity of PFI1625c: correlation analysis of protein-peptide molecular models. J. Mol. Graph. Model. 43:21-30. |
|
|
Lipinski CA (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv. Drug Deliv. Rev. 101:34-41. |
|
|
Lounnas V, Ritschel T, Kelder J, McGuire R, Bywater RP, Lounnas V, Ritschel T, Kelder J, McGuire R, Bywater RP, Foloppe N (2013). Current progress in structure-ased rational drug design marks a new mindset in drug discovery. Comput. Struct. Biotechnol. J. 5:e201302011. |
|
|
MacDonald CA, Boyd RJ (2015). Molecular docking study of macrocycles as Fk506-binding protein inhibitors. J. Mol. Graph. Model. 59(Suppl. C):117-122. |
|
|
Maier JKX, Labute P (2014) Assessment of fully automated antibody homology modeling protocols in molecular operating environment. Proteins: Structure, Function, and Bioinformatics 82(8):1599-1610. |
|
|
Margolis R, Derr L, Dunn M, Huerta M, Larkin J, Sheehan J, Guyer M, Green ED (2014). The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data. J. Am. Med. Inform. Assoc. 21(6):957-958. |
|
|
March-Vila E, Pinzi L, Sturm N, Tinivella A, Engkvist O, Chen H, Rastelli G (2017). On the integration of in silico drug design methods for drug repurposing. Front. Pharmacol. 8:298-306. |
|
|
Mehra A, Jerath G, Ramakrishnan V, Trivedi V (2015). Characterization of ICAM-1 biophore to design cytoadherence blocking peptides. J. Mol. Graph. Model. 57(Suppl. C):27-35. |
|
|
Méndez-Lucio O, Naveja JJ, Vite-Caritino H, Prieto-Martínez FD, Medina-Franco JL (2016). Review. One Drug for Multiple Targets: A Computational Perspective. J. Mex. Chem. Soc. 60(3):168-181. |
|
|
Paul P, Chowdhury A, Das Talukdar A, Choudhury MD (2015). Homology modeling and molecular dynamics simulation of N-myristoyltransferase from Plasmodium falciparum: An insight into novel antimalarial drug design. J. Mol. Model. 21(3):37-43. |
|
|
Pandey R, Mohmmed A, Pierrot C, Khalife J, Malhotra P, Gupta D (2014). Genome wide in silico analysis of Plasmodium falciparum phosphatome. BMC Genom. 15(1):1024-1030. |
|
|
Peltenburg H, Groothuis FA, Droge ST, Bosman IJ, Hermens JL (2013). Elucidating the sorption mechanism of "mixed-mode" SPME using the basic drug amphetamine as a model compound. Anal. Chem. Acta 782:21-27. |
|
|
Raza M, Khan Z, Ahmad A, Raza S, Khan A, Mohammadzai IU. (2017). In silico 3-D structure prediction and molecular docking studies of inosine monophosphate dehydrogenase from Plasmodium falciparum. Comput. Biol. Chem. 71:10-19. |
|
|
Ren JX, Gao NN, Cao XS, Hu QA, Xie Y (2016). Homology modeling and virtual screening for inhibitors of lipid kinase PI(4)K from Plasmodium. Biomed. Pharmacother. 83:798-808. |
|
|
Rout S, Warhurst DC, Suar M, Mahapatra RK (2015). In silico comparative genomics analysis of Plasmodium falciparum for the identification of putative essential genes and therapeutic candidates. J. Microb. Methods 109 (Suppl. C):1-8. |
|
|
Rout S, Mahapatra RK (2016). In silico screening of novel inhibitors of M17 leucine amino peptidase (LAP) of Plasmodium vivax as therapeutic candidate. Biomed. Pharmacother. 82:192-201. |
|
|
Sharma D, Soni R, Patel S, Joshi D, Bhatt TK (2016). In-silico studies on DegP protein of Plasmodium falciparum in search of anti-malarials. J. Mol. Model. 22(9):201-211. |
|
|
Sullivan DJ, Liu Y, Mott BT, Kaludov N, Martinov MN (2015). Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity. PLoS ONE 10(5):e0125593. |
|
|
Verma S, Debnath U, Agarwal P, Srivastava K, Prabhakar YS (2015). In silico exploration for new antimalarials: arylsulfonyloxy acetimidamides as prospective agents. J. Chem. Info. Model. 55(8):1708-1719. |
|
|
Villalobos TP, Ibarra R, Acosta JJ (2013). 2D, 3D-QSAR and molecular docking of 4(1H)-quinolones analogues with antimalarial activities. J. Mol. Graph. Model. 46:105-124. |
|
|
Webb B, Sali A (2014). Protein structure modeling with MODELLER. Methods Mol. Biol. 1137:1-15. |
|
|
World Health Organization (WHO) (2015). World Malaria Report 2015. World Health Organization: Geneva, Switzaerland. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
